Related Experiment Video
Updated: Aug 13, 2025

12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.9K
T cell exhaustion in malignant gliomas
Matthew B Watowich1, Mark R Gilbert1, Mioara Larion1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Trends in Cancer
|January 21, 2023
Summary
T cell exhaustion hinders immunotherapy for malignant gliomas. Understanding the glioma microenvironment
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Immunotherapy shows promise in various cancers but faces challenges in CNS malignancies.
- T cell exhaustion is a key mechanism limiting anti-tumor immunity in the CNS.
Purpose of the Study:
- To review recent advances in understanding T cell exhaustion drivers in the glioma microenvironment.
- To discuss factors contributing to T cell exhaustion in brain cancers.
- To highlight potential strategies for overcoming T cell exhaustion and improving immunotherapy.
Main Methods:
- Review of current literature on T cell exhaustion in glioma.
- Analysis of extrinsic and intrinsic factors influencing T cell function in the CNS.
- Identification of potential therapeutic targets for reversing T cell exhaustion.
Main Results:
- T cell exhaustion is characterized by impaired effector function, increased inhibitory receptor expression, metabolic deficits, and altered epigenetics/transcription.
- Specific microenvironmental factors within gliomas promote T cell exhaustion.
- Both external and internal factors contribute to this immunosuppressive phenotype.
Conclusions:
- T cell exhaustion is a significant barrier to effective immunotherapy for malignant gliomas.
- Targeting specific immunosuppressive mechanisms within the glioma microenvironment is crucial.
- Reversing T cell exhaustion could represent a major breakthrough in brain cancer immunotherapy.

